Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 25, 2025Acta Facultatis Medicae NaissensisOpen Access

Assessment of treatment outcomes in multiple myeloma according to prognostic factors and therapeutic approach

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDragana DraškovićGMGoran MarjanovicMVMiodrag Vučić

Discussion

Loading...

Member takes

Overview

Retrospective analysis of treatment outcomes highlights the importance of risk stratification in multiple myeloma.

Key Points

  • This study assesses treatment outcomes in multiple myeloma concerning therapeutic approaches and prognostic factors.
  • Retrospective-prospective analysis of 200 patients with multiple myeloma
  • Evaluation of treatment modality, disease biology, and clinical status
  • Assessment of progression-free survival and overall survival across prognostic subgroups
  • Best responses achieved with first-line VTD regimen in patients with good performance status
  • CTD protocol showed longest average overall survival in patients under 65
  • PAD regimen yielded highest response rates in second-line therapy
  • Elderly patients with high Charlson Comorbidity Index benefitted most from MPT regimen
  • Vel-Dex linked to highest progression rates

Cite This Study

Drašković et al. (2025) studied this question.

synapsesocial.com/papers/692502d187af00ed34ac2723https://doi.org/10.5937/afmnai41-60811
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis2025
  2. 2Survival and clinical response to bortezomib, thalidomide, and dexamethasone in patients with multiple myeloma at a peruvian tertiary care center: A real-world retrospective observational study2025
  3. 3Multiple myeloma in 2026 — current guidelines and new therapies2026
  4. 4Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025
  5. 5Prognosis of multiple myeloma patients based on histopathological evaluation of bone marrow.2025